Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-SPINK1-2
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
si-SPINK1-2 is a specific small interfering RNA (siRNA) sequence designed to silence the expression of the Serine Peptidase Inhibitor Kazal Type 1 (SPINK1) gene. SPINK1 has been identified as a marker for an aggressive subtype of prostate cancer, where its overexpression promotes malignant cellular behaviors including proliferation, migration, and invasion. In research settings, si-SPINK1-2 is utilized to induce the degradation of SPINK1 mRNA, thereby reducing protein levels and attenuating the oncogenic phenotype in SPINK1-positive cell lines such as 22Rv1. This experimental tool is critical for validating SPINK1 as a therapeutic target and understanding the biological mechanisms underlying SPINK1-mediated cancer progression.
- Other names
- SPINK1 siRNASPINK-1 siRNASPINK 1 siRNAsi-SPINK1si-SPINK-1si-SPINK 1
02
Targets
SPINK1 (Serine peptidase inhibitor Kazal-type 1)
Beyond the preview
Go deeper on si-SPINK1-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on si-SPINK1-2.